Brevan Howard Capital Management’s Corcept Therapeutics CORT Stock Holding History

Brevan Howard Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$323K	Buy	8,016 +718	+10%	+$26.8K	﹤0.01%	1575
2025 Q4	$254K	Buy	7,298 +3,957	+118%	+$311K	﹤0.01%	1457
2025 Q3	$278K	Sell	3,341 -41,661	-93%	-$3.01M	﹤0.01%	1601
2025 Q2	$3.3M	Buy	+45,002	New	+$3.26M	0.02%	533
2025 Q1	–	Sell	-8,423	Closed	-$424K	–	1204
2024 Q4	$424K	Buy	+8,423	New	+$441K	﹤0.01%	667

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Brevan Howard Capital Management's CORT Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Corcept Therapeutics (CORT) stake by 9.8% in Q1 2026, buying an estimated $26.8K and bringing the position to 8,016 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #1575.

Brevan Howard Capital Management first reported a position in CORT in Q4 2024 and has held it in 5 quarters since. The position peaked at $3.3M in Q2 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Brevan Howard Capital Management held 8,016 shares of Corcept Therapeutics worth $323K as of Q1 2026.
Brevan Howard Capital Management bought 718 Corcept Therapeutics shares in Q1 2026, an estimated $26.8K.
Corcept Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1575 holding.
Brevan Howard Capital Management first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 5 quarters since.
Brevan Howard Capital Management's Corcept Therapeutics position peaked at $3.3M in Q2 2025.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.